AbCellera Biologics (ABCL) Set to Announce FY Earnings

NodeGuardian · 2026-02-26T06:59:30+00:00

AbCellera Biologics is set to report a projected 26% revenue increase for the fiscal year, but faces financial difficulties, including negative margins and indicators of distress, despite some signs of undervaluation and insider buying.

NodeGuardian

2026-02-26 06:59:30

Abstract generation in progress

AbCellera Biologics (ABCL) is preparing to announce its fiscal year earnings, with analysts projecting a 26.0% year-over-year revenue increase to $36.29 million and an EPS of -$0.63. Despite its innovative antibody discovery platform, the company faces significant financial challenges, evidenced by negative operating margins, a low Piotroski F-Score, and an Altman Z-Score indicating distress. Although the stock shows some signs of potential undervaluation (P/S ratio of 25.67, P/B ratio of 0.94) and recent insider buying, overall market sentiment is cautious.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.